Aakash Desai, MD, MPH, FASCO

Thoracic/Phase 1 Oncologist @ONealCancerUAB, Asst Prof @UABMedicine | Alum @MayoHemeOnc @UConnIM @MDAndersonNews| Co-Host @HemOncFellows 🎙️ @LungCancerRX

[Aakash Desai, MD, MPH, FASCO @ADesaiMD]

As #oncologytrainees prepare for their first #patientencounter, the #SPIKES protocol is often a good starting point. What advise do you have for #trainees when #deliveringbadnews? @marklewismd @NarjustDumaMD @GlopesMd @mtmdphd @VPrasadMDMPH @DevikaDasMD @MayoHemeOnc #HOFellowLife

[Aakash Desai, MD, MPH, FASCO @ADesaiMD]

POSEIDON showed adding tremelimumab to durva+chemo improves OS in metastatic NSCLC.
TRIDENT asks: in whom?
#ML signature flags KRAS/STK11-mut, subset we call IO-resistant, as benefiting most (top 50% non-sq: OS HR 0.56).
Post-hoc, but consistent? 🫁 https://t.co/IBM8rePBFD

[#TumorBoardTuesday @TumorBoardTues]

#TumorBoardTuesday
🧐We have had TBT🗣️on the efficacy of 🚫EGFR Tx4⃣EGFRmut🧬#NSCLC
🤔But what to do w/progression on these🎯💊❓

📢Join us Tuesday, 07-07-26 at 8PM ET as @DDoroshow & @nh_osei 🗣️ Tx options for EGFRi RESISTANT #NSCLC

RT and bring others into the discussion‼️

[Miguel Gonzalez Velez, MD @mgonzalezvelMD]

@JTCancerCenter opening first-in-human trial of ML261, a potency-enhanced anti-DLL3 CAR T therapy, in relapsed SCLC and NEC. Advancing cellular therapies in solids. @ADesaiMD @salmanpunekar #LCSM #SCLC https://t.co/huVO4Ohqt1

[Chinmay Jani @Jani_Chinmay]

Tune in for my conversation with @Lung_Cancers regarding our project evaluating #AI for clinical decision making in patients with #EGFR positive #NSCLC @SylvesterCancer @HemOncMiami @GlopesMd @Latinamd @lungoncdoc @ADesaiMD @EGFRResisters @jillfeldman4

[Eric K. Singhi, MD @lungoncdoc]

Ph 3 SigVie-002 Press Release

▫️Sigvotatug vedotin (IB-6 directed ADC) failed to improve OS vs docetaxel in previously treated metastatic non-squamous NSCLC.
▫️? Signal observed in 2L setting.

Negative study. Ongoing Ph 3 study of SV + pembro in 1L mNSCLC w/ PD-L1 ≥50%

[LARVOL @Larvol]

We’re excited to share that eight of our abstracts (six posters and two ePosters) have been accepted at @IASLC - #WCLC26.

Our abstracts cover:
• AI-simulated polling
• Multi-LLM decision support
• Cross-trial analytics
• Survival outcome prediction

These submissions reflect a tremendous team effort. We’re grateful to our collaborators and colleagues whose expertise and dedication made this work possible.

Proud of what we’ve built together and looking forward to contributing to the conversations at WCLC 2026.

Get data-driven and real-time insights with CLIN 👉 https://t.co/ct6tMIQHii

#LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #LungCancer #LCSM #WCLC2026 | @brunolarvol | @Jud_Prz | @Jani_Chinmay | @dan_morgen | @FionnualaCrowle | @BenBleibergMD | @ADesaiMD | @GlopesMd | @lungoncdoc | @Debarat07333230 | @MedinDarko | @RinkeyPal | @Davdwlkerson

[LungCancerRx 🫁💊 @LungCancerRx]

NEW episode of #LungCancerRx is out!

Expert guest @FSkoulidis breaks down KRAS, STK11, and KEAP1 mutant NSCLC.

@ADesaiMD @FawziAbuRous @lungoncdoc @OncNewsCentral

https://t.co/rGfG2xLnAF

[Eric Topol @EricTopol]

For medical information, general AI frontier models (Google, OpenAI, Anthropic) outperformed specialized @EvidenceOpen and @UpToDate as assessed by 12 US clinicians, randomized and blinded to which model and extensive testing/benchmarks. This was not anticipated. @NatureMedicine
https://t.co/KCH1ADfQWz

[Sameer Deshmukh,MD @SamdeshmukhMD]

With the #BestMentorEver @ADesaiMD. I can't describe in words the amount of love, respect and admiration I have for him.

Wouldn't be standing here today if it wasn't for his mentorship and support.

Check out his newest venture https://t.co/ZIyrDwliAb

#ASCO26

[Sanad Alhushki @SanadAlhushki]

My first ASCO definitely lived up to my expectations, so happy to catch up with friends, colleagues and mentors!

A great way to wrap up my time as a research fellow, and now getting ready for my intern year.

#ASCO26

[Aakash Desai, MD, MPH, FASCO @ADesaiMD]

Definitely an exciting advance in a subgroup in need for more therapies! Looking forward to seeing this be replicated in global context!

[Eric K. Singhi, MD @lungoncdoc]

Ph 3 #HARMONi6: OS in 1L advanced sqNSCLC.

Ivonescimab + chemo improved OS vs tislelizumab + chemo:
▫️mOS 27.9 vs 23.7 mos (HR 0.66)

Benefit across PD-L1 subgroups:
▫️PD-L1 <1%: NE vs 18.6 mos (HR 0.64)
▫️PD-L1 ≥1%: NE vs 27.3 mos (HR 0.68)

#ASCO26 @ASCO

[Balazs Halmos @BalazsHalmosMD]

LIBRETTO-432 - excellent RETurn on investment for this pivotal study of selpercatinib vs placebo in pts with resected RET fusion positive NSCLC (with most having also received adjuvant chemo)

With HR of 0.17 for EFS in st 2/3 pts this study easily achieved its primary endpoint and along w reasonable safety profile will definitely sell selpercatinib!

One just wonders- in rare mol subsets with so clearly anticipatable outcomes (eg post chemo-XRT, ErbB2/zongertinib, ROS/taletrectinib) will this added to ADAURA/ALINA provide impetus for new study designs not calling for placebo arms?

So Dr. Goldman delivered gold in his terrific presentation and selpercatinib seems like clear new SOC for high risk resected pts- now we just need to make sure we find all appropriate pts through careful expanded biomarker testing which is now a necessity in early stage NSCLC!
#ASCO26 #lcsm

[Eric K. Singhi, MD @lungoncdoc]

OVERALL SURVIVAL DOUBLED!!!!!
In pancreatic cancer. 🤯

That alone is remarkable. But what also stands out is seeing a KRAS-targeted therapy generate an OS curve like this in a disease where meaningful advances have historically been SO difficult! #ASCO26 @ASCO

[Christine A. Garcia, MD, MPH @christinemphmd]

@drteplinsky @ADesaiMD

[Christine A. Garcia, MD, MPH @christinemphmd]

Fresh data from #ASCO26 shows a massive blind spot: online resources about AI in cancer care are largely low-quality & completely omit the risks of AI hallucination & misinformation.

We need a major push for AI literacy to protect patients! 🛑🤖 #OncTwitter #CancerCare #meded

[Chinmay Jani @Jani_Chinmay]

And here is our poster presentation . @SylvesterCancer @ASCOTECAG @GlopesMd @Latinamd @lungoncdoc @ADesaiMD @brunolarvol

[LARVOL @Larvol]

We're presenting at @ASCO 2026!

Evaluating AI decision support in a rapidly evolving therapeutic landscape: EGFR-mutant metastatic NSCLC.

📍 Poster Board #548
🕘 9:00 AM CT

If you're attending ASCO 2026, stop by our poster and connect with the team. We look forward to the discussion.

Abstract link 👉 https://t.co/cBYIDqsGmD

Explore more insights and conference data from #ASCO26 👉 https://t.co/7DT5JCwVFe

#LARVOL #ASCO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #ClinicalOncology #LungCancer #NSCLC #LCSM | @Jani_Chinmay | @Jud_Prz | @Ankitowledge |
@Debarat07333230 | @Kyle__Edwards | @rafikelbebmd | @brunolarvol | @lungoncdoc | @Latinamd | @ADesaiMD | @GlopesMd | @dan_morgen

[IDEOlogy Health @IDEOlogyHealth]

Tonight's IDEO Xchange focused on targeted lung cancer. Join the discussion live - right here on X - with Drs. @Latinamd @GlopesMd @ASridharMD @RManochakian @BZhangMD @LealTiciana @MNagasaka @ChristianRolfo @JoelNealMD @BRicciutiMD @ADesaiMD Matthew Gumbleton and Jeffrey Ward.

[gilberto lopes @GlopesMd]

OptiTROP-Lung05 (Abs 8506): sac-TMT (TROP2 ADC) + pembro vs pembro, 1L PD-L1+ NSCLC. mPFS not reached vs 5.7 mo, HR 0.35, P<.0001; 12-mo PFS 62.4% vs 29.0% . First ADC + IO combo to hit its primary endpoint in 1L NSCLC . Chemo-free challenge to pembro±chemo. (Lancet)

Non-US Standard comparator though - not ready for prime time

#ASCO26 @OncoAlert @OncBrothers @StephenVLiu @Jani_Chinmay @asco @myESMO @glopesmd @SylvesterCancer @latinamd @iaslc @COlazagasti @openevidence @openmedicinehq @narjustflorezmd

[gilberto lopes @GlopesMd]

ASCO26 First Look Video: Dr. Andrew Armstrong on TALAPRO-3 https://t.co/TzkbAVJC2O

#ASCO26 @OncoAlert @OncBrothers @StephenVLiu @Jani_Chinmay @asco @myESMO @glopesmd @SylvesterCancer @latinamd @iaslc @COlazagasti @openevidence @openmedicinehq @narjustflorezmd @lungoncdoc @drshieldsmd @jackwestmd @n8pennell @mtmdphd @drarturoai @larvol @onclive @rmanochakian @devikadasmd @dryukselurun @dan_morgen @ptarantinomd